Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today the availability of a 4th generation HIV antigen/antibody combination assay and a new diagnostic algorithm that improves screening for HIV infection.
Earlier detection of HIV can improve individual treatment and help reduce the spread of HIV in the population. New 4th generation HIV assays have the ability to detect both the HIV antibodies (IgG and IgM) and the HIV p24 antigen simultaneously prior to seroconversion. On average, the 4th generation assay allows for detection of HIV seven days earlier in acutely infected individuals than would be possible with 3rd generation assays. These assays are an important enhancement to LabCorp's test menu, which encompasses the most comprehensive, cost-effective diagnostic products available to provide physicians and their patients critical information for the screening, diagnosis and treatment of multiple disease states.